S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NYSE:VOR

Vor Biopharma (VOR) Stock Price, News & Analysis

$2.37
+0.16 (+7.24%)
(As of 03/28/2024 ET)
Today's Range
$2.21
$2.38
50-Day Range
$1.80
$2.43
52-Week Range
$1.62
$5.70
Volume
482,143 shs
Average Volume
295,255 shs
Market Capitalization
$161.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

Vor Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
469.6% Upside
$13.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Vor Biopharma in the last 14 days
Based on 22 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.34) to ($1.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.61 out of 5 stars

Medical Sector

279th out of 938 stocks

VOR stock logo

About Vor Biopharma Stock (NYSE:VOR)

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

VOR Stock Price History

VOR Stock News Headlines

Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Vor Biopharma (NYSE:VOR) Earns "Outperform" Rating from Wedbush
Vor Biopharma: Q4 Earnings Insights
VOR Apr 2024 5.000 call
See More Headlines
Receive VOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
N/A
Sub-Industry
N/A
Fax
N/A
Employees
168
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.50
High Stock Price Target
$17.50
Low Stock Price Target
$11.00
Potential Upside/Downside
+469.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
59,716,000
Market Cap
$161.56 million
Optionable
Not Optionable
Beta
-0.38
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Robert Ang M.B.A. (Age 49)
    M.D., MBBS, President, CEO & Director
    Comp: $875.51k
  • Dr. Nathan D. Jorgensen M.B.A. (Age 47)
    Ph.D., Chief Financial Officer
    Comp: $608.48k
  • Dr. Tirtha Chakraborty Ph.D. (Age 51)
    Chief Scientific Officer
    Comp: $622.96k
  • Dr. Siddhartha Mukherjee DPHIL (Age 53)
    M.D., Ph.D., Scientific Founder & Chairman of Scientific Advisory Board
  • Ms. Tania Philipp (Age 52)
    Chief People Officer
  • Dr. Robert G. Pietrusko Pharm. D. (Age 76)
    Pharm.D., Chief Regulatory Officer
  • Mr. John C. King M.B.A. (Age 48)
    Chief Commercial Officer
  • Dr. Eyal C. Attar M.D. (Age 53)
    Chief Medical Officer
  • Mr. Samir Vattompadam M.S.
    Senior Vice President of Portfolio Strategy & Program Management
  • Mr. David Phillips M.B.A.
    Senior VP & Head of Quality

VOR Stock Analysis - Frequently Asked Questions

Should I buy or sell Vor Biopharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vor Biopharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VOR shares.
View VOR analyst ratings
or view top-rated stocks.

What is Vor Biopharma's stock price target for 2024?

5 Wall Street analysts have issued 12 month target prices for Vor Biopharma's stock. Their VOR share price targets range from $11.00 to $17.50. On average, they anticipate the company's share price to reach $13.50 in the next year. This suggests a possible upside of 469.6% from the stock's current price.
View analysts price targets for VOR
or view top-rated stocks among Wall Street analysts.

How have VOR shares performed in 2024?

Vor Biopharma's stock was trading at $2.25 at the start of the year. Since then, VOR stock has increased by 5.3% and is now trading at $2.37.
View the best growth stocks for 2024 here
.

When is Vor Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VOR earnings forecast
.

How were Vor Biopharma's earnings last quarter?

Vor Biopharma Inc. (NYSE:VOR) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.12.

When did Vor Biopharma IPO?

Vor Biopharma (VOR) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel served as the underwriters for the IPO.

Who are Vor Biopharma's major shareholders?

Vor Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.57%), Vanguard Group Inc. (2.57%), Northern Trust Corp (0.59%), Exchange Traded Concepts LLC (0.09%), Barclays PLC (0.08%) and Goldman Sachs Group Inc. (0.06%).
View institutional ownership trends
.

How do I buy shares of Vor Biopharma?

Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:VOR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners